🔗 Share this article

As the United States continues making sweeping changes to its immunization recommendations, an unexpected name has emerged unexpectedly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on coronavirus shots during the global health crisis and has zeroed in on alleged deaths following Covid vaccination in her brief time at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Program

Agency leaders were set to unveil radical revisions to the pediatric immunization program in December, synchronizing the US with the Danish national calendar, according to reports – a substantial departure that would place the US at odds with much of the global community with little proof for benefit. The planned update has been delayed until the coming year.

In place of the director of the vaccine center, Dr. Høeg is set to speak at the event. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

Consolidating Power at the FDA

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad solidify control at the regulatory agency – and it points to a renewed priority upon reevaluating previously authorized immunizations at the FDA.

Høeg has repeatedly called for discontinuing some childhood immunization guidelines in the US to become more like Denmark's approach, a country with nationalized medicine and a number of inhabitants about the size of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Expertise

The appointee has little discernible background in medication creation, approval processes or leadership, which has been typical for past directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a major agency. She is not an expert in drug approvals.”

Former commissioners of the center would “grasp legal statutes and the research of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she has not acquired the type of experience that previous people who ran the center have had.”

This division has an enormous workload at the FDA, the former commissioner stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office authorizes numerous generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and each of these have to be looked after,” she noted. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

There is also, a significant leadership component to the position, which oversees more than 5,000 personnel. “It is a huge administrative position, if you do it right,” Woodcock added.

Agency Reaction and Controversial Initiatives

In response to concerns about Høeg’s qualifications and whether this appointment represents increased cooperation among FDA leaders on immunizations, a spokesperson said that the “inquiries are based on flawed premises”.

“Her resume aligns with the duties of her job,” the official explained, pointing to the months Høeg spent advising the agency head on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a contentious rapid drug-approval program that apparently worried her former heads. “By what process are these drugs being selected for this fast-track system? Who makes the calls?” Dr. Howard said. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer rules of pharmaceuticals, except for immunizations.”

Documented History on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if troubling, past, some experts have noted. She published a study using unconfirmed volunteer-provided data to estimate the frequency of myocarditis following COVID-19 vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are riskier than they are.

Part of her “desired changes” for the new administration included changing regulations for novel immunizations and halting “non-essential” vaccines, she said post-election on a audio program. At the agency, Høeg has reportedly proposed barring teenage boys from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who starts off with her conclusions and tailors the evidence to retrofit the data in a extremely misleading, untruthful way,” Dr. Howard argued.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|